Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis)

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1139-1148

  Koh, Gavin C K W ^a,b,c,d,e   Meijers, Joost C M ^a   Maude, Rapeephan R ^b   Limmathurotsakul, Direk ^b   Day, Nicholas P J ^b,f   Peacock, Sharon J ^b,c,e   van der Poll, Tom ^a   Wiersinga, Willem J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Burkholderia pseudomallei; Coagulation; Diabetes mellitus; Fibrinolysis; Melioidosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; IMIPENEM; INSULIN; MEROPENEM; METFORMIN; PROTHROMBIN; SULFONYLUREA DERIVATIVE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD CLOTTING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; THROMBOCYTE FUNCTION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; BURKHOLDERIA PSEUDOMALLEI; DIABETES COMPLICATIONS; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MELIOIDOSIS; MIDDLE AGED; SEPSIS;

EID: 82555171691     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-07-0504     Document Type: Article

References (41)

1. Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8: R82-90.
2. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
3. Esper A, Moss M, Martin G. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Critical Care 2009; 13: R18.
4. Stegenga ME, Vincent J-L, Vail GM, et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2010; 38: 539-545.
5. Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55:1807-1812.
6. Stegenga ME, van der Crabben SN, Blümer RME, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008; 112: 82-89.
7. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 2007; 24: 1168-1171.
8. Tsai CL, Lee CC, Ma MH, et al. Impact of diabetes on mortality among patients with community-acquired bacteremia. J Infect 2007; 55: 27-33.
9. Thomsen RW, Hundborg HH, Lervang H-H, et al. Diabetes and outcome of community- acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2004; 27: 70-76.
10. Haug JB, Harthug S, Kalager T, et al. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome. Clin Infect Dis 1994; 19: 246-256.
11. Kornum JB, Thomsen RW, Riis A, et al. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007; 30: 2251-2257.
12. Thomsen RW, Hundborg HH, Lervang H-H, et al. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis 2005; 40: 628-631.
13. Graham BB, Keniston A, Gajic O, et al. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 2010; 38: 16-24.
14. Wuthiekanun V, Peacock SJ. Management of melioidosis. Expert Rev Anti Infect Ther 2006; 4: 445-455.
15. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31: 981-986.
16. White NJ. Melioidosis. Lancet 2003; 361: 1715-1722.
17. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/ clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-853.
18. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4: e900.
19. Koh GCKW, Maude RR, Schreiber MF, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011; 52: 717-725.
20. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999; 29: 408-413.
21. Lo TJ, Ang LW, James L, et al. Melioidosis in a tropical city state, Singapore. Emerging Infect Dis 2009; 15: 1645-1647.
22. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18: 383-416.
23. Wiersinga WJ, Meijers JCM, Levi M, et al. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6: 32-39.
24. Limmathurotsakul D, Wuthiekanun V, Chierakul W, et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol 2005; 43: 2274-2276.
25. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
26. McCane DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994; 308: 1323-1328.
27. World Health Organization. Part 1: Diagnosis and classification of diabetes mellitus. In: Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, World Health Organization; 1999.
28. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138.
29. Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17: 445-451.
30. de Pont A-CJM, Bakhtiari K, Hutten BA, et al. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006; 134: 213-219.
31. Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metabolism 2002; 51: 471-476.
32. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
33. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
34. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999; 48: 1156-1161.
35. LaRosa SP, Opal SM, Utterback B, et al. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10: 25-31.
36. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
37. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
38. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
39. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-1199.
40. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886.
41. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? Br Med J 2009; 339: b4432.